Cisatracurium for acute respiratory distress syndrome: review of current evidence

Abstract

I 2 = 0%), overall mortality (RR = 0.73, 95% CI = 0.57-0.92, I 2 = 0%), number of cases of new-onset barotrauma (RR = 0.43, 95% CI = 0.2-0.9, I 2 = 0%) and number of ventilator-free days (MD = 1.91, 95% CI = 0.28-3.55, I 2 = 0%). However, they did not show any significant effect on the duration of mechanical ventilation (RR 1.14, 95% CI =-4.07-6.35, I 2 = 0%) or number of cases of new-onset critical illness neuromyopathy (RR 1.13, 95% CI = 0.76-1.67, I 2 = 0%). Conclusion Our analysis showed that the early, short use of a continuous infusion of cisatracurium led to a statistically significant reduction in mortality in ARDS patients. The potential effects and drawbacks of the intervention were discussed.